THAC, The Healthy Aging Company, is a French and US-based privately-owned biopharmaceutical company which has the ambition to develop a range of first-in-class drug candidates targeting T2DM and its complications.
♦ Its pipeline could lead to potential real game changers for patient care and disease management.THAC is primarily focused on Type 2 Diabetes Mellitus, a condition with still unmet medical needs.
♦ THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations).
♦ THAC drug candidates have a unique and innovative mechanism of action that targets oxidation and inflammation.
♦ THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death and prevent T2DM complications ; peripheral neuropathy is a severe complication for which there is no treatment available; e.g., diabetic foot wounds and amputations.
A Scientific Advisory Board with world renowned leaders in metabolism and diabetes
THAC set up a Strategic Advisory Board (SAB) composed of prominent figures from the academic world to expand its research and development strategic capabilities.
Members are internationally renowned scientific leaders in metabolism and diabetes, some being consultants for regulatory agencies (US FDA, EU EMA).
The THAC’s team is honored to benefit from their knowledge and fruitfull expertise.
Pr Christophe Magnan is the Chairman of the Scientific Advisory Board.
Prof. Fabrizzio Andreelli, MD, PhD
CHU Pitié-Salpétrière Paris
Head of Department Diabetology
Prof. Jean-François Gautier, MD, PhD
CHU Lariboisière, Paris
Head of Department
Prof. Bernard Thorens, PhD
Professor UNIL Lausanne
University of biology and medicine
Head of GIG department (centre intégratif génomique)
Prof. Robert Eckel, MD, PhD
Professor of Medicine Emeritus
University Cincinnati, USA
Prof. Stefano Del Prato, MD, PhD
Professor endocrinology and
metabolism President EASD
School of Medicine, University Pisa, Italy
Chief of section Diabetes
Pr Agnes Hartemann, PhD, MD
Professor diabetologist CHU Pitié-Salpétrière
Paris, Head of Diabetology Service
Expert diabetic wounds & foots